Indivior PLC (NASDAQ:INDV – Get Free Report) shares crossed above its fifty day moving average during trading on Thursday. The stock has a fifty day moving average of $35.24 and traded as high as $37.00. Indivior shares last traded at $35.25, with a volume of 5,718,744 shares trading hands.
Analyst Ratings Changes
A number of equities research analysts have weighed in on INDV shares. Craig Hallum reaffirmed a “buy” rating and issued a $53.00 target price on shares of Indivior in a report on Tuesday, August 4th. Wall Street Zen lowered Indivior from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Barclays lifted their target price on Indivior from $43.00 to $45.00 and gave the company an “overweight” rating in a research report on Wednesday. Weiss Ratings downgraded Indivior from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, September 24th. Finally, Zacks Research raised shares of Indivior from a “hold” rating to a “strong-buy” rating in a report on Friday, October 2nd. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $46.40.
Check Out Our Latest Report on Indivior
Indivior Stock Performance
The firm has a market cap of $4.17 billion, a price-to-earnings ratio of 9.88 and a beta of 0.87. The business has a fifty day simple moving average of $35.20 and a 200-day simple moving average of $35.62.
Indivior (NASDAQ:INDV – Get Free Report) last announced its quarterly earnings results on Thursday, October 29th. The company reported $1.32 EPS for the quarter, beating analysts’ consensus estimates of $1.06 by $0.26. The firm had revenue of $356.00 million for the quarter, compared to analyst estimates of $329.35 million. Indivior had a negative return on equity of 418.04% and a net margin of 32.75%. On average, equities analysts anticipate that Indivior PLC will post 3.66 earnings per share for the current year.
Indivior Announces Dividend
The firm also recently announced a special dividend, which will be paid on Friday, November 6th. Investors of record on Friday, October 30th will be given a dividend of $8.13 per share.
Insider Buying and Selling
In other Indivior news, CAO Woodrow D. Anderson bought 1,500 shares of Indivior stock in a transaction on Thursday, August 27th. The shares were purchased at an average cost of $35.69 per share, with a total value of $53,535.00. Following the acquisition, the chief accounting officer directly owned 27,638 shares of the company’s stock, valued at $986,400.22. The trade was a 5.74% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.74% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On Indivior
A number of hedge funds have recently modified their holdings of the business. Rockefeller Capital Management L.P. lifted its stake in Indivior by 512.4% in the fourth quarter. Rockefeller Capital Management L.P. now owns 1,286 shares of the company’s stock valued at $46,000 after buying an additional 1,076 shares during the period. TD Waterhouse Canada Inc. acquired a new stake in shares of Indivior during the 2nd quarter worth approximately $63,000. GAMMA Investing LLC acquired a new stake in shares of Indivior during the 2nd quarter worth approximately $66,000. China Universal Asset Management Co. Ltd. increased its stake in shares of Indivior by 11.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 21,533 shares of the company’s stock valued at $788,000 after acquiring an additional 2,129 shares in the last quarter. Finally, Vise Technologies Inc. increased its stake in shares of Indivior by 33.0% in the 3rd quarter. Vise Technologies Inc. now owns 9,298 shares of the company’s stock valued at $333,000 after acquiring an additional 2,306 shares in the last quarter. Institutional investors and hedge funds own 60.33% of the company’s stock.
About Indivior
Indivior PLC (NASDAQ:INDV) is a global pharmaceutical company focused on developing and commercializing medicines for substance use disorders and serious mental health conditions. Its portfolio is centered on treatments for opioid use disorder, opioid overdose, and related medical needs.
The company’s principal products include Sublocade, an extended-release buprenorphine injection for opioid use disorder; Suboxone, a buprenorphine and naloxone treatment available in film and other formulations; and Opvee, a nalmefene nasal spray intended for the emergency treatment of known or suspected opioid overdose.
Read More
- Five stocks we like better than Indivior
- Starbucks Says Its Turnaround Is Done—The Numbers Make a Strong Case (With 1 Catch)
- 3 Robotics ETFs, 3 Different Ways to Bet on Humanoid Robots
- Can Microsoft Turn a Leaner Workforce and Record AI Spending Into Bigger Profits?
- Why JFrog Could Be the Software Infrastructure Company to Beat in the AI Boom
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.
